Sun Pharmaceutical Reports 27% Net Profit Increase in Q1 FY27

Sun Pharmaceutical Industries Limited has reported a significant increase in its net profit for the first quarter of fiscal year 2027, reflecting a 27% year-on-year rise to ₹2,895 crore, as per statements released on July 31, 2026. The company’s overall revenue from operations rose by 10% to ₹15,300 crore, boosted by a strong performance in the domestic market and its innovative medicines segment. The financial results indicate that Sun Pharmaceutical’s operating profit, which is defined as earnings before interest, taxes, depreciation, and amortisation (EBITDA), increased by 3% to ₹4,418 crore compared to the same period last year. However, the EBITDA margin saw a contraction, falling to 28.9% down from 31.06% in Q1 FY26. In terms of geographical performance, the company’s sales in India reached ₹5,475 crore, marking an impressive growth of 16%. This segment accounted for 36.1% of total consolidated sales, while the firm’s market share rose to 8.5% from 8.2%, as reported by Pharmarack for the MAT period ending June 2026. Sun Pharma launched five new products in India during this quarter. The research and development investment was reported at ₹826 crore, which constitutes 5.4% of sales in the quarter. The company filed three Abbreviated New Drug Applications (ANDAs) and received approvals for six ANDAs throughout the period. Sun Pharmacy's pipeline includes 57 approved New Drug Applications (NDAs), with 13 additional NDAs pending approval from the United States Food and Drug Administration (FDA). Despite the strong domestic performance, the company faced challenges in the US market where formulation sales dipped by 9.7% to $427 million, contributing roughly 26.6% of total consolidated sales. This decline in the generic sector was somewhat mitigated by growth in the innovative medicines division. Conversely, sales from emerging markets reached $311 million, an increase of 4.2%, representing 19.4% of total consolidated sales, while international markets accounted for $218 million or 13.6% of overall sales. The global innovative medicines segment reported sales of $351 million, marking a 12.8% increase, thus contributing 21.9% to overall revenue. The Managing Director of Sun Pharmaceutical, Kirti Ganorkar, noted, “Our performance during the quarter was driven by strong momentum in India as well as Innovative Medicines, which delivered robust growth across the U.S. and international regions. Recent semaglutide approvals in India, Brazil, and South Africa underscore our capabilities in developing complex peptide products for patients globally.” Furthermore, the company is set to proceed with the acquisition of Organon following the approval by its shareholders, with completion expected in early 2027. Following the release of the earnings report, Sun Pharmaceutical's shares were valued at ₹1,991 each on the National Stock Exchange, reflecting a decline of 0.5%.